On Monday, Heron Therapeutics Inc (NASDAQ: HRTX) was -2.58% drop from the session before settling in for the closing price of $1.55. A 52-week range for HRTX has been $1.04 – $3.93.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 17.85%. When this article was written, the company’s average yearly earnings per share was at 83.89%. With a float of $151.02 million, this company’s outstanding shares have now reached $151.70 million.
Let’s determine the extent of company efficiency that accounts for 126 employees. In terms of profitability, gross margin is 67.55%, operating margin of -17.61%, and the pretax margin is -19.0%.
Heron Therapeutics Inc (HRTX) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Heron Therapeutics Inc stocks. The insider ownership of Heron Therapeutics Inc is 0.71%, while institutional ownership is 80.25%.
Heron Therapeutics Inc (HRTX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 83.89% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 47.50% during the next five years compared to 20.01% growth over the previous five years of trading.
Heron Therapeutics Inc (NASDAQ: HRTX) Trading Performance Indicators
You can see what Heron Therapeutics Inc (HRTX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.74. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.62.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.18, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach -0.06 in one year’s time.
Technical Analysis of Heron Therapeutics Inc (HRTX)
Looking closely at Heron Therapeutics Inc (NASDAQ: HRTX), its last 5-days average volume was 1.47 million, which is a drop from its year-to-date volume of 2.69 million. As of the previous 9 days, the stock’s Stochastic %D was 38.89%. Additionally, its Average True Range was 0.13.
During the past 100 days, Heron Therapeutics Inc’s (HRTX) raw stochastic average was set at 39.83%, which indicates a significant increase from 11.90% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 46.31% in the past 14 days, which was lower than the 97.71% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.5448, while its 200-day Moving Average is $2.3888. However, in the short run, Heron Therapeutics Inc’s stock first resistance to watch stands at $1.5533. Second resistance stands at $1.5967. The third major resistance level sits at $1.6333. If the price goes on to break the first support level at $1.4733, it is likely to go to the next support level at $1.4367. Should the price break the second support level, the third support level stands at $1.3933.
Heron Therapeutics Inc (NASDAQ: HRTX) Key Stats
There are 152,095K outstanding shares of the company, which has a market capitalization of 222.49 million. As of now, sales total 127,040 K while income totals -110,560 K. Its latest quarter income was 32,810 K while its last quarter net income were -4,850 K.
